Amy E. DeZern - Concepedia

Author

Amy E. DeZern

Johns Hopkins University ORCID

Also Known As

A DeZern, A Dezern, A E DeZern, A E Dezern, A. DeZern, A. Dezern, A. E. DeZern, Amy DeZern, Amy Dezern, Amy E DeZern

496

Publications

10.5K

Citations

H-Index

125

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Moffitt Cancer Center The University of Texas MD Anderson Cancer Center Cleveland Clinic

About

Amy E. DeZern is an author at Johns Hopkins University specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	45	2.6K
2	Health Sciences	9	9	604
3	Public Health	4	4	111
4	Engineering	2	2	70
5	Social Sciences	1	1	26

Amy E. DeZern

130

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, New England Journal of Medicine	2020	519
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero, Journal of Clinical Oncology	2021	436
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Blood	2015	297
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, Journal of the National Comprehensive Cancer Network Hematological MalignancyOncologyDiagnostic ClassificationBone Marrow FailureDiagnostic Criteria	2016	293
Diagnostic utility of telomere length testing in a hospital-based setting Jonathan K. Alder, Vidya Sagar Hanumanthu, Margaret A. Strong, Proceedings of the National Academy of Sciences	2018	267
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults Yvette L. Kasamon, Javier Bolaños‐Meade, Gabrielle T. Prince, Journal of Clinical Oncology	2015	237
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma, Blood	2020	205
Loss-of-function mutations in the RNA biogenesis factor <i>NAF1</i> predispose to pulmonary fibrosis–emphysema Susan E. Stanley, Dustin L. Gable, Christa L. Wagner, Science Translational Medicine Advanced Lung DiseaseLung InflammationGeneticsGenomic MechanismPulmonary Alveolar Proteinosis	2016	199
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS Christopher G. Kanakry, Hua-Ling Tsai, Javier Bolaños‐Meade, Blood	2014	196
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide Shannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry, Haematologica ImmunologySurgeryImmunotherapyTranslational MedicineBone Marrow Failure	2016	186

Page 1